RACING to Bring Life Back to Life
8.1.2021 16:53:00 EET | Business Wire | Press release
The riders and staff of the Tour de France 2020 winning team UAE Team Emirates have taken the UAE Ministry of Health & Prevention approved COVID-19 vaccine developed by Sinopharm CNBG following the success of the #4Humanity trials facilitated by G42 Healthcare in the UAE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210108005321/en/
Tour de France 2020 winner Tadej Pogacar receives Covid-19 vaccine in Abu Dhabi, United Arab Emirates (Photo: AETOSWire)
A total of 27 riders, including the Tour de France 2020 winner Slovenian cyclist Tadej Pogačar, plus 32 staff have now received the vaccine.
Commenting on receiving the vaccine, UAE Team Emirates Principal Mauro Gianetti said: “As a UAE team we are enormously proud of the efforts the nation and its Leadership has taken at every level to both combat the impact the of the COVID-19 pandemic and to be a leader in the efforts to bring life back to normal.”
“The whole team is delighted to have been given the opportunity to protect ourselves and others through taking the vaccine and we would like to congratulate the UAE and all partners of this program for their incredible work to make this happen.”
About G42 Healthcare
G42 Healthcare, a subsidiary of Abu Dhabi-based Group 42 – a leading technology company, is committed to developing a world-class, sustainable healthcare sector in the UAE. At the forefront in the battle against COVID-19, G42 Healthcare uses its advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conduct research into new vaccines and drug therapies, and map trends in the outbreak including virus mutations. The company was responsible was conducting the world’s first phase III clinical trial of inactivated vaccines across the Pan Arab region with over 43,000 volunteers participating from over 125 nationalities.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210108005321/en/
Contact information
APCO Worldwide
Reem Abi Ali, +971559648763
G42@apcoworldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 09:00:00 EEST | Press release
Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidates that demonstrated real, measurable activity against tumors. This collaboration marks an important milestone for Okomera, which is signing its first commercial agreement with an international pharmaceutical group. Under the terms of the agreement, Servier will operate Okomera’s platform fully independently. Its teams will be able to ge
Bureau Veritas: Double Digit Total Revenue Growth in the Third Quarter of 202621.10.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): The execution of LEAP | 28 has transformed Bureau Veritas into a more focused, faster-growing and higher-performing multi-specialist company. Its Product Line-centric operating model combines the Company’s global scale and resilience with clear priorities, stronger accountability and deep specialist expertise. This creates a more repeatable growth model, enabling faster execution, stronger capabilities and higher conversion of growth into profitability. Q3 2026 Key figures1 › New reporting structure effective July 1st, 2026, comprising four divisions: Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services, excluding the planned for exit businesses of Oil & Petrochemicals and Coal Testing and Inspection, and “Government Services”; › Revenue of EUR 1,569.7 million, up 10.1% year-on-year and up 6.2% organically; • Positive scope effect of 1.8%, from accelerated bolt-on acquisitions (+2.7% contribution), net of
AI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study Finds21.10.2026 08:00:00 EEST | Press release
Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty, according to The CEO Response, Egon Zehnder's third annual study of 843 global chief executives. Nearly half of CEOs (48%) consider the adoption and impact of AI an extremely critical challenge, up from 37% in 2025. Geopolitical instability (44%) and economic uncertainty (40%) follow, while 62% expect geopolitical disruption to increase over the next 12 months. These challenges are shaping where CEOs are focusing their efforts. Half (50%) identify AI investment among the three most important changes they're making to their organizations, followed by innovation (48%) and improving their cost base (41%). By comparison, 29% selected upskilling and talent development as a top priority. “CEOs can invest in AI much faster than they can change how an organization works,” said Francesco Buquicchio, Global CEO of Egon Zehnder. “That gap matters. L
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership21.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company will present eight scientific abstracts, alongside a symposium and six Meet-the-Expert sessions, all highlighting the expanding benefits of Relfydess, Sculptra, and the Restylane range.1-8 Together, the data demonstrate Galderma’s commitment to meeting the evolving needs of patients and healthcare professionals through innovation that addresses growing needs, from menopause-related skin changes and regenerative aesthetic solutions, to body indications. Data across face and body indications showcase the power of Sculptra and Restylane Data on Sculptra, the first proven regenerative biostimulator, will be shared at AMWC Dubai, following its approval in the UAE expanding its current clinical application for the face to include key body areas:
Sihoo esittelee uuden sukupolven ergonomisia toimistoratkaisuja ORGATEC 2026 -messuilla20.10.2026 21:14:00 EEST | Tiedote
ORGATEC 2026 -messujen lähestyessä ergonomisten istuinratkaisujen asiantuntija Sihoo esittelee uuden sukupolven työympäristöratkaisujaan hallissa 8.1, osastoilla A-060 ja B-061. Messujen teeman ”Tiloista vuorovaikutukseen: tilojen suunnittelu jatkuvasti muuttuvassa maailmassa” mukaisesti Sihoo esittelee, kuinka mukautuva ergonominen suunnittelu tukee asentojen vaihtelua ja nykyaikaisten työympäristöjen muuttuvia tarpeita. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261020772047/fi/ Sihoo ORGATEC 2026 -messuilla Kölnissä Käyttötilanteisiin perustuva elämyksellinen tila Avoimeen tilakonseptiin perustuvalla Sihoon osastolla yhdistyvät oranssin ja valkoisen värimaailma, kerrokselliset kattorakenteet, läpikuultavat väliseinät ja integroitu valaistus. Korkeussäädettävillä työpöydillä ja näytöillä varustetut työpisteet sekä yhteistyöhön suunnitellut istuma-alueet jäljittelevät tuttuja toimistoympäristöjä ja havainnollistavat,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom